Business Context and Reporting Period
This Form 8-K, dated August 24, 2025, reports that MannKind Corporation ("Parent") has entered into a definitive Agreement and Plan of Merger to acquire scPharmaceuticals Inc. ("Target"). The transaction involves a tender offer followed by a merger, with the Target surviving as a wholly-owned subsidiary of MannKind. The filing also details related financing amendments and support agreements executed on the same date.
Key Financial Metrics and Transaction Terms
- Offer Price: $5.35 in cash per share plus one non-tradeable Contingent Value Right (CVR).
- CVR Milestone Payments: Up to $1.00 per share in aggregate contingent cash payments based on FDA approval of an injection product (SCP-111) and net sales milestones for Injection Products and FUROSCIX Infusors.
- Financing: MannKind secured an additional $175.0 million incremental delayed draw term loan to finance transaction costs. Up to $75.0 million of existing delayed draw commitments were made available for transaction funding.
- Debt Repayment: Upon closing, MannKind is obligated to repay and buy out Target's indebtedness and revenue purchase rights with Perceptive Credit Holdings IV, LP, estimated at $81.0 million (assuming a September 30, 2025 closing).
- Termination Fee: $9.48 million payable by the Target to MannKind under specified termination circumstances.
- Principal Stockholder Support: Principal Stockholders (including the CEO and OrbiMed affiliates) own approximately 11.5% of Target shares and have agreed to tender and vote in support of the transaction.
Material Changes and Conditions
The filing represents a material change in MannKind's corporate structure and strategy, marking a shift into cardiorenal medicine through the acquisition of FUROSCIX. The transaction is subject to several conditions, including:
- Receipt of more than 50% of Target shares in the tender offer.
- Expiration of the Hart-Scott-Rodino Antitrust waiting period.
- Absence of a material adverse effect on the Target.
- Truth and accuracy of representations and warranties.
The tender offer is not subject to a financing condition. The offer is expected to remain open for twenty business days following commencement.
Guidance, Outlook, and Risks
Management Commentary and Outlook: MannKind anticipates the acquisition will diversify and accelerate double-digit revenue growth over the next decade. The company plans to submit a supplemental New Drug Application for the FUROSCIX autoinjector in the third quarter of 2025. The transaction is expected to strengthen MannKind's position in cardiometabolic and lung diseases.
Risks and Contingencies:
- CVR Uncertainty: There is no assurance that the FDA approval or sales milestones required for CVR payments will be achieved by the specified deadlines (September 30, 2026, or December 31, 2026).
- Regulatory and Legal: Risks include failure to obtain regulatory approvals, potential legal proceedings, and antitrust review delays.
- Integration: Risks associated with successfully integrating the Target's business, retaining key employees, and realizing expected synergies.
- Financing: Risks related to meeting conditions to draw down the necessary funding from the Loan Agreement.
Important Facts for Investor Verification
- Verify the specific terms and conditions of the tender offer in the upcoming Schedule TO filing.
- Confirm the exact closing date to validate the $81.0 million debt buyout estimate, as this figure assumes a September 30, 2025 closing.
- Review the CVR Agreement (Annex III to the Merger Agreement) for detailed definitions of "Milestone 1" and "Milestone 2" and the specific sales thresholds required.
- Monitor the status of the Hart-Scott-Rodino antitrust review and any potential regulatory challenges.
- Assess the impact of the $175.0 million incremental debt on MannKind's future liquidity and leverage ratios.